loading
Precedente Chiudi:
$4.26
Aprire:
$4.2
Volume 24 ore:
5.81M
Relative Volume:
3.02
Capitalizzazione di mercato:
$696.31M
Reddito:
$25.55M
Utile/perdita netta:
$-341.97M
Rapporto P/E:
-1.5465
EPS:
-2.69
Flusso di cassa netto:
$-304.44M
1 W Prestazione:
-11.68%
1M Prestazione:
-10.73%
6M Prestazione:
-39.27%
1 anno Prestazione:
-60.42%
Intervallo 1D:
Value
$4.15
$4.315
Intervallo di 1 settimana:
Value
$4.11
$5.025
Portata 52W:
Value
$4.11
$12.14

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name
Nome
Relay Therapeutics Inc
Name
Telefono
617-370-8837
Name
Indirizzo
399 BINNEY STREET, CAMBRIDGE
Name
Dipendente
294
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
RLAY's Discussions on Twitter

Confronta RLAY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RLAY
Relay Therapeutics Inc
4.16 696.31M 25.55M -341.97M -304.44M -2.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-10 Ripresa Goldman Buy
2024-09-10 Aggiornamento Jefferies Hold → Buy
2024-09-10 Downgrade Oppenheimer Outperform → Perform
2024-05-10 Aggiornamento Barclays Equal Weight → Overweight
2023-04-20 Aggiornamento Jefferies Underperform → Hold
2023-04-19 Aggiornamento Raymond James Outperform → Strong Buy
2023-04-13 Iniziato Raymond James Outperform
2023-02-03 Iniziato Oppenheimer Outperform
2022-09-30 Iniziato Barclays Equal Weight
2022-09-02 Iniziato Stifel Buy
2022-06-06 Iniziato Jefferies Underperform
2022-02-01 Iniziato Berenberg Buy
2021-07-21 Iniziato BofA Securities Buy
2020-12-15 Reiterato H.C. Wainwright Buy
2020-12-08 Iniziato JMP Securities Mkt Outperform
2020-11-05 Iniziato H.C. Wainwright Buy
2020-08-10 Iniziato Cowen Outperform
2020-08-10 Iniziato Goldman Buy
2020-08-10 Iniziato Guggenheim Buy
2020-08-10 Iniziato JP Morgan Neutral
Mostra tutto

Relay Therapeutics Inc Borsa (RLAY) Ultime notizie

pulisher
Dec 20, 2024

Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail

Dec 20, 2024
pulisher
Dec 20, 2024

Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Dec 20, 2024
pulisher
Dec 20, 2024

Relay Therapeutics Inc (RLAY) Volatility Hits 7.89% – Here Is What You Should Do - Stocks Register

Dec 20, 2024
pulisher
Dec 19, 2024

Relay Therapeutics stock hits 52-week low at $4.25 By Investing.com - Investing.com Canada

Dec 19, 2024
pulisher
Dec 18, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 100,000 Shares - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year LowHere's What Happened - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Relay Therapeutics CEO Sanjiv Patel sells $500,000 in stock - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Relay Therapeutics CEO Sanjiv Patel sells $500,000 in stock By Investing.com - Investing.com UK

Dec 18, 2024
pulisher
Dec 18, 2024

Relay Therapeutics stock hits 52-week low at $4.25 - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

HighTower Advisors LLC Cuts Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by HighTower Advisors LLC - Defense World

Dec 18, 2024
pulisher
Dec 17, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Dec 17, 2024
pulisher
Dec 17, 2024

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.4%Time to Sell? - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.58 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Dec 17, 2024
pulisher
Dec 17, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Relay Therapeutics: A Hidden Gem in Cancer Treatment with RLY-2608's Potential to Revolutionize Breast Cancer Care - mediahousepress

Dec 16, 2024
pulisher
Dec 16, 2024

Relay Therapeutics' SWOT analysis: stock's potential in PI3K inhibitor race By Investing.com - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Relay Therapeutics' SWOT analysis: stock's potential in PI3K inhibitor race - Investing.com India

Dec 16, 2024
pulisher
Dec 15, 2024

Relay Therapeutics’ (RLAY) Market Outperform Rating Reiterated at JMP Securities - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - MSN

Dec 13, 2024
pulisher
Dec 12, 2024

Relay Therapeutics stock holds Buy rating, BofA highlights $1bn+ peak sales potential for RLY-2608 - Investing.com Nigeria

Dec 12, 2024
pulisher
Dec 12, 2024

Relay Therapeutics' (RLAY) Market Outperform Rating Reiterated at JMP Securities - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - Marketscreener.com

Dec 12, 2024
pulisher
Dec 12, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World

Dec 12, 2024
pulisher
Dec 12, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace

Dec 12, 2024
pulisher
Dec 12, 2024

Relay Therapeutics Announces Updated Interim Data for - GlobeNewswire

Dec 12, 2024
pulisher
Dec 11, 2024

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewswire Inc.

Dec 11, 2024
pulisher
Dec 09, 2024

Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar - BioCentury

Dec 09, 2024
pulisher
Dec 09, 2024

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - The Manila Times

Dec 09, 2024
pulisher
Dec 09, 2024

Relay Therapeutics to Present Updated Clinical Data on - GlobeNewswire

Dec 09, 2024
pulisher
Dec 08, 2024

Elevar Therapeutics’ Global Licensing Agreement with Relay Therapeutics - Global Legal Chronicle

Dec 08, 2024
pulisher
Dec 08, 2024

1,349,400 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Bought by Point72 Asset Management L.P. - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

FY2024 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

HC Wainwright Predicts Lower Earnings for Relay Therapeutics - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

Leerink Partners Cuts Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World

Dec 07, 2024
pulisher
Dec 07, 2024

Leerink Partnrs Has Positive Outlook of RLAY FY2024 Earnings - Defense World

Dec 07, 2024
pulisher
Dec 07, 2024

Relay Therapeutics price target lowered to $18 from $19 at Leerink - MSN

Dec 07, 2024
pulisher
Dec 06, 2024

After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) - Yahoo Finance

Dec 06, 2024
pulisher
Dec 04, 2024

Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now? - Insider Monkey

Dec 04, 2024
pulisher
Dec 04, 2024

Elevar nabs Relay’s FGFR2 rare cancer drug in $500M deal - BioWorld Online

Dec 04, 2024
pulisher
Dec 04, 2024

Relay Therapeutics stock sees target decrease, strong potential for lirafugratinib - Investing.com

Dec 04, 2024
pulisher
Dec 04, 2024

Relay Therapeutics stock target cut by Leerink amid licensing agreement - Investing.com UK

Dec 04, 2024
pulisher
Dec 04, 2024

Maven Securities LTD Takes $2.39 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat

Dec 04, 2024
pulisher
Dec 04, 2024

Relay Therapeutics stock hits 52-week low at $4.48 By Investing.com - Investing.com South Africa

Dec 04, 2024
pulisher
Dec 03, 2024

Relay Therapeutics stock hits 52-week low at $4.48 - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - The Manila Times

Dec 03, 2024
pulisher
Dec 03, 2024

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewswire

Dec 03, 2024
pulisher
Dec 01, 2024

Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials (NASDAQ:RLAY) - Seeking Alpha

Dec 01, 2024
pulisher
Dec 01, 2024

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Bellevue Group AG - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Braidwell LP Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat

Nov 30, 2024

Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Capitalizzazione:     |  Volume (24 ore):